Subclinical hypothyroidism may be associated with elevated high-sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia

Endocrine Journal

Volumn 52, Issue 1, 2005, Pages 89-94

  Tuzcu, Alpaslan ^a,b   Bahceci, Mithat ^a   Gokalp, Deniz ^a   Tuzun, Yekta ^a   Gunes, Kemal ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Fasting insulin and insulin resistance; Prolactin; Subclinical hypothyroidism

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PROLACTIN; THYROID HORMONE; THYROTROPIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOTHYROIDISM; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; MALE; THYROID HORMONE BLOOD LEVEL; THYROXINE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; FASTING; FEMALE; HUMANS; HYPERINSULINISM; HYPOTHYROIDISM; INFLAMMATION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 15744385276     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.52.89     Document Type: Article

References (24)

1. Kabadi UM (1993) Subclinical hypothyroidism. Natural course of the syndrome during a prolonged follow-up study. Arch Intern Med 153: 957-961.
2. Kushner I, Sehgal AR (2002) Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? Arch Intern Med 162: 867-869.
3. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC (2000) Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 132: 270-278.
4. Tieche M, Lupi GA, Gutzwiller F, Grob PJ, Studer H, Burgi H (1981) Borderline low thyroid function and thyroid autoimmunity. Risk factors for coronary heart disease? Br Heart J 46: 202-206.
5. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Rodgers H, Tunbridge F, Young ET (1996) The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 6: 155-160.
6. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 321: 199-204.
7. Fowler FB, Ikram H, Banim O (1972) Serum-cholesterol, thyroid failure, and coronary-artery disease. Lancet 1: 7752: 685.
8. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ, Muller B (2003) Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo controlled trial. Atherosclerosis 166: 379-386.
9. Pepys MB (1981) C-reactive protein fifty years on. Lancet 1: 653-657.
10. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl J Med 342: 836-843.
11. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J (2000) C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20: 2094-2099.
12. Zwaka TP, Hombach V, Torzewski J (2001 ) C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103: 1194-1197.
13. Davidson MH (2002) Management of dyslipidemia by the patient profiles. In the Mobile Lipid Clinic. A Companion Handbook. Lippincott Williams and Wilkins, Philadelphia, 182-184.
14. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD (1999) von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. Arterioscler Thromb Vasc Biol 19: 3071-3078.
15. Lindeman RD, Schade DS, LaRue A, Romero LJ, Liang HC, Baumgartner RN, Koehler KM, Garry PJ (1999) Subclinical hypothyroidism in a biethnic, urban community. J Am Geriatr Soc 47: 703-709.
16. Festa A, D'Agostino R, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, Haffher SM (1999) Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19: 562-568.
17. Reis FM, Reis AM, Coimbra CC (1997) Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats. J Endocrinol 153: 423-428.
18. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26: 341-346.
19. Bahceci M, Tuzcu A, Bahceci S, Tuzcu S (2003) Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 26: 655-659.
20. Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28: 138-142.
21. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC (2000) The Colorado thyroid disease prevalence study. Arch Intern Med 160: 526-534.
22. Michalopoulou G, Alevizaki M, Piperingos G, Mitsibounas D, Mantzos E, Adamopoulos P Koutras DA (1998) High serum cholesterol levels in persons with 'high normal' TSH levels: Should one extend the definition of subclinical hypothyroidism. Eur J Endocrinol 138: 141-145.
23. Bakker SJL, Ter Matten JC, Popp-Snijders C, Slaets JPJ, Heine RJ, Gans ROB (2001) The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 86: 1206-1211.
24. Ness GC, Lopez D, Chambers CM, Newsome WP, Cornelius P, Long CA, Harwood HJ Jr (1998) Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression. Biochem Pharmacol 56: 121-129.